SUNITINIB TREATMENT MODIFICATION IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA: ANALYSIS OF A REAL-WORLD SWEDISH COHORT

被引：0
|
作者：
Jakobsson, M. [1 ]
Nilsson, F. [1 ]
Strambi, A. [2 ]
Arpegard, J. [2 ]
Dalen, J. [3 ]
机构：
[1] Pfizer Innovat AB, Sollentuna, Sweden
[2] Pfizer Innovat AB, Stockholm, Sweden
[3] ICON Plc, Stockholm, Sweden
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA26
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [21] Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1067 - 1067
  • [22] PHARMACOECONOMIC EVALUATION OF SUNITINIB MALATE FOR FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO
    Tenorio, C.
    Vargas, J.
    Rizo-Rios, P.
    Flores-Gil, O.
    Martinez-Fonseca, J.
    Mould-Quevedo, J.
    Davila-Loaiza, G.
    VALUE IN HEALTH, 2009, 12 (03) : A44 - A45
  • [23] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    UROLOGIE, 2023, 62 (08): : 830 - 839
  • [24] Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
    Geynisman, Daniel M.
    Faccone, Jillian
    Zhang Ying
    Ejzykowicz, Flavia
    Stwalley, Brian
    Hamilton, Melissa
    Le, Trong Kim
    Huo, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [25] Treatment patterns: Targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Hess, Gregory P.
    Borker, Rohit
    Fonseca, Eileen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [26] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
    Lalani, Aly-Khan A.
    Li, Haocheng
    Heng, Daniel Y. C.
    Wood, Lori
    Kalirai, Austin
    Bjarnason, Georg A.
    Sim, Hao-Wen
    Kollmannsberger, Christian K.
    Kapoor, Anil
    Hotte, Sebastien J.
    Vanhuyse, Marie
    Czaykowski, Piotr
    Reaume, M. Neil
    Soulieres, Denis
    Venner, Peter
    North, Scott
    Basappa, Naveen S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
  • [27] Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population.
    Strambi, Angela
    Jakobsson, Maria
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [28] Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
    Lalani, A-K.
    Li, H.
    Heng, D.
    Wood, L.
    Kalirai, A.
    Bjarnason, G.
    Sim, H-W.
    Kollmannsberger, C. K.
    Kapoor, A.
    Hotte, S. J.
    Vanhuyse, M.
    Czaykowski, P.
    Reaume, M. N.
    Soulieres, D.
    Venner, P.
    North, S.
    Basappa, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab
    Doshi, Gurjyot K.
    Robert, Nicholas J.
    Chen, Liwei
    Chan, Philip K.
    Del Tejo, Viviana
    Stwalley, Brian
    Huo, Stephen
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [30] Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population
    Jakobsson, Maria
    Strambi, Angela
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    FUTURE ONCOLOGY, 2024, 20 (20) : 1385 - 1392
12345